InsiderTradr

SkinBioTherapeutics plc (SBTX.L)

LSE · GBp · Healthcare · Biotechnology

£5.50 (-4.35%) as of

Key statistics

Market cap
14.25M
Forward P/E
29.10
EPS (TTM)
-0.00
Dividend yield
0.00%
52-week range
0.10 – 23.00
Beta
0.26
Revenue (TTM)
5.23M
Profit margin
-8.73%
Analyst target
£29.00
Volume
144.30k

About SkinBioTherapeutics plc

SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development. The company has an agreement with Croda Plc for the development of SkinBiotix as an active ingredient for the skicare and cosmetic industry. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Driffield, the United Kingdom.

Sector
Healthcare
Industry
Biotechnology
Headquarters
Driffield, United Kingdom
Employees
41

skinbiotherapeutics.com

Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.

Related stocks